Nektar Therapeutics/$NKTR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
- Ticker
- $NKTR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 63
- Headquarters
- San Francisco, United States
- Website
- www.nektar.com
NKTR Metrics
BasicAdvanced
$1.3B
-
-$6.47
1.16
-
Price and volume
Market cap
$1.3B
Beta
1.16
52-week high
$109.00
52-week low
$33.40
Average daily volume
1.5M
Financial strength
Current ratio
10.416
Quick ratio
9.708
Long term debt to equity
0.125
Total debt to equity
0.151
Interest coverage (TTM)
-4.22%
Profitability
EBITDA (TTM)
-129.95
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-287.84%
Operating margin (TTM)
-239.32%
Effective tax rate (TTM)
-0.04%
Revenue per employee (TTM)
$870,000
Management effectiveness
Return on assets (TTM)
-12.54%
Return on equity (TTM)
-35.75%
Valuation
Price to revenue (TTM)
17.298
Price to book
1.47
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
-4.023
Free cash flow yield (TTM)
-24.86%
Free cash flow per share (TTM)
-9.662
Growth
Revenue change (TTM)
-27.15%
Earnings per share change (TTM)
-25.83%
3-year revenue growth (CAGR)
-14.63%
10-year revenue growth (CAGR)
-11.77%
3-year earnings per share growth (CAGR)
-35.80%
10-year earnings per share growth (CAGR)
-7.77%
What the Analysts think about NKTR
Analyst ratings (Buy, Hold, Sell) for Nektar Therapeutics stock.
Analyst projections of the future price of Nektar Therapeutics stock.
Bulls say / Bears say
In the Phase 2b atopic dermatitis trial, rezpegaldesleukin reduced EASI scores by 61% at week 16 at the leading dose, versus 31% with placebo, and met key secondary endpoints. This gives Nektar’s lead programme encouraging evidence as it moves through Phase 3. (The Lancet)
Longer follow-up in alopecia areata suggests the treatment’s effects may persist: five of eight responders still met the SALT ≤20 threshold six months after stopping, and some patients’ responses deepened off treatment. The follow-up cohort was small, but the results point to a potentially differentiated treatment profile. (Nektar Therapeutics)
Nektar reported $1.02 billion in cash and investments at the end of June 2026, with a projected cash runway into Q3 2028—past its expected mid-2028 initial Phase 3 atopic dermatitis readouts. That reduces the risk of a near-term funding gap before an important catalyst. (Nektar Therapeutics)
The pivotal atopic dermatitis readouts are not expected until mid-2028, and Nektar’s first planned biologics licence application is in 2029. Investors face a long wait with substantial trial and regulatory risk before the lead drug could generate sales. (Nektar Therapeutics)
Injection-site reactions affected about 70% of patients receiving rezpegaldesleukin in the Phase 2b atopic dermatitis trial, versus 4% on placebo. Nearly all were mild to moderate and resolved, but frequent reactions could still weigh on comfort and adherence in a chronic condition. (The Lancet)
Nektar remains loss-making: first-half 2026 revenue was $21.0 million against a net loss of $85.5 million, while it raised about $1.07 billion through equity-based financings between July 2025 and April 2026. Continued clinical spending could mean further cash burn and dilution for shareholders. (Nektar Therapeutics, CapEdge)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
NKTR Financial Performance
Revenues and expenses
NKTR Earnings Performance
Company profitability
Upcoming events
No upcoming events
NKTR News
AllArticlesVideos
Funds containing NKTR
Fund name | Fund size | $NKTR weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.02% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.